News | January 14, 2015

UH Case Medical Center First to Offer Novel HeartFlow CT-FFR Technology

Non-invasive test determines impact of specific lesions on blood flow

HeartFlow, CT-FFR, computed tomography fractional flow reserve, UH Case Medical

Image courtesy of HeartFlow Inc.

January 14, 2015 — University Hospitals (UH) Case Medical is now offering a new, non-invasive test for coronary artery disease designed to help physicians develop the right treatment plan for each patient. Developed by HeartFlow Inc., computed tomography-fractional flow reserve (CT-FFR) is a non-invasive imaging technology specifically designed to offer insight on both the extent of the blockage, as well as whether it is impacting blood flow to the heart. UH Case Medical Center’s Daniel Simon, M.D., will be first to use the CT-FFR test in the United States.

Most other diagnostic tests are designed to provide information to clinicians regarding a patient’s overall risk of having coronary artery disease, but they cannot help the clinician determine the extent to which a specific blockage is impeding blood flow to the heart.

The CT-FFR platform was developed by marrying non-invasive 3-D imaging with computational fluid dynamics technology to produce detailed models of a patient’s cardiovascular anatomy. For every patient, CT-FFR performs millions of complex equations simulating blood flow in the coronary arteries to provide mathematically computed FFR values from images derived using non-invasive CT angiography. Fractional flow reserve values demonstrate blood pressure differences around a lesion to determine whether it is likely to reduce blood flow to the heart. These simulated values help physicians determine the right course of action for each patient. 

“CT-FFR represents a tremendous advancement in the diagnosis of coronary artery disease,” said Simon, president, Harrington Heart & Vascular Institute at UH Case Medical Center and Herman K. Hellerstein Chair and professor of medicine at Case Western Reserve University School of Medicine. “Historically, we have been faced with either using tests we knew were not always accurate or putting a patient through an invasive procedure just to determine whether they needed another invasive procedure. For the first time, we have access to a diagnostic that is both non-invasive and highly accurate in showing us the extent of a lesion, as well as how it can hinder blood flow through the vessel. I believe CT-FFR has the potential to completely change the way we manage coronary artery disease globally.”

Clinical data from the HeartFlow NXT study demonstrated superior discriminatory ability to identify lesions that have the potential to impede blood flow when compared to coronary CT angiography alone. In the study, published in the Journal of the American College of Cardiology in 2014, CT-FFR had higher diagnostic accuracy (86 percent) than coronary CT angiography (65 percent). This difference is primarily due to a significantly increased specificity with CT-FFR (86 percent) compared to coronary CT angiography (60 percent). Invasive angiography performed with 71 percent accuracy in the study.

With the improved data, patients will not have to undergo unnecessary procedures or further invasive or time-consuming testing associated with coronary artery disease.

For more information: www.heartflow.com

Related Content

Siemens Healthineers Announces First U.S. Install of Somatom go.Top CT
News | Computed Tomography (CT) | September 17, 2018
September 17, 2018 — The Ohio State University Wexner Medical Center in Columbus recently became the first healthcare
Key Patient Preparations for a CT Scan
News | Computed Tomography (CT) | September 05, 2018
The Center for Diagnostic Imaging (CDI) in Miami recently released a list of important preparations patients should...
Videos | Computed Tomography (CT) | July 25, 2018
A discussion with Patricia Dickson, LRT(CT), director of imaging and outpatient services, Capital Cardiology Associat
Videos | Computed Tomography (CT) | July 23, 2018
Ed Nicol, M.D., FSCCT, MBA, head of cardiac CT, Royal Brompton Hospital, London, and chair of the Society of Cardiova
Videos | Computed Tomography (CT) | July 17, 2018
An interview with Patrick Serruys, M.D., Ph.D., Imperial College London, principal investigator of the SYNTAX III Tri
Zebra Medical Vision Announces FDA 510(k) Clearance of Coronary Calcium Algorithm
Technology | Computed Tomography (CT) | July 12, 2018
Zebra Medical Vision has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Coronary...
IAC Awards First CT Accreditation for a Mobile Stroke Unit
News | Computed Tomography (CT) | July 09, 2018
The Intersocietal Accreditation Commission (IAC) recently recognized the University of Tennessee Health Science Center...
FFR-CT may soon replace invasive angiography for coronary lesion assessment. #EuroPCR 

Anexample of a clinical case of CT-FFR, which can derive the FFR numbers for their entire coronary tree using a noninvasive CT scan.

Feature | Computed Tomography (CT) | May 29, 2018
May 29, 2018 — Results from the innovative SYNTAX III Revolution Trial [1] underline the effectiveness of evolving no
James Min Named Editor-in-Chief of Journal of Cardiovascular Computed Tomography
News | Computed Tomography (CT) | May 01, 2018
James K. Min, M.D., FSCCT, has been selected for a five-year term as the new editor-in-chief of the Journal of...
FDA Clears Siemens' Somatom go.All, go.Top CT Scanners
Technology | Computed Tomography (CT) | April 18, 2018
April 18, 2018 — The U.S.
Overlay Init